14 results
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
against us alleging that Ketamir-2, MIRA-55 or one of our other product candidates caused an injury. While we continue to take what we believe … demand for Ketamir-2, MIRA-55 or our other product candidates if such product candidates are approved;
injury to our reputation;
withdrawal of clinical
8-K
EX-10.1
MIRA
Mira Pharmaceuticals Inc
20 Nov 23
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
8:10am
, liability or damage for personal injury, property damage or otherwise, including reasonable attorneys’ fees, (collectively “Claims”), arising directly
424B4
MIRA
Mira Pharmaceuticals Inc
4 Aug 23
Prospectus supplement with pricing info
1:01pm
, and in the future, an individual may bring a liability claim against us alleging that MIRA1a or one of our product candidates caused an injury … outcome, liability claims may result in:
decreased demand for MIRA1a and our product candidates if such product candidates are approved;
injury to our
424B1
MIRA
Mira Pharmaceuticals Inc
4 Aug 23
Prospectus with pricing info
12:59pm
, an individual may bring a liability claim against us alleging that MIRA1a or one of our product candidates caused an injury. While we continue to take … result in:
decreased demand for MIRA1a and our product candidates if such product candidates are approved;
injury to our reputation;
withdrawal
S-1
pd29rmbvfdsnrig7h
29 Jun 23
IPO registration
4:39pm
S-1
EX-10.5
mz5mt ngdy1ev9tiqeb
29 Jun 23
IPO registration
4:39pm
DRS/A
EX-10.5
2t9h7idzsf9tclywnby9
8 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
9p85e
8 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
3rb ggt6ywhj1
2 May 23
Draft registration statement (amended)
12:00am
DRS
81ccqfj
29 Jun 22
Draft registration statement
12:00am
- Prev
- 1
- Next